TILs Indicate Outcome in Young Patients Not Receiving Systemic Adjuvant Treatment for TNBC
Tumour infiltrating lymphocyte levels may inform treatment decisions in women younger than 40 years with triple negative breast cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
TERT Promoter Mutations May Not Be Indicative of Sensitivity To Temozolomide
TERT promoter mutation may not be linked to MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma
The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment Option in Advanced Clear Cell RCC
Nivolumab plus cabozantinib as first-line treatment for advanced clear cell renal cell carcinoma was consistently superior to sunitinib across all subgroups studied
Neoadjuvant Atezolizumab Is Safe in Resectable NSCLC
Findings from the PRINCEPS study
Long-term Analysis Shows Nivolumab Bests Ipilimumab in Resected Stage IIIB-C/IV Melanoma
CheckMate 238 results at 4-years consistently favour nivolumab across all parameters evaluated
Abemaciclib Improves OS in Combination with Tamoxifen in HR-positive, HER2-negative Metastatic Breast Cancer
Final overall survival analysis of the nextMONARCH study
Elderly Patients with Stage III Colon Cancer May Derive Less Benefit from Adjuvant Oxaliplatin and Flouropyrimidines
Relapse-free interval rates in TOSCA study were poorer in elderly compared with younger patients
Whole Genome Sequencing Is Feasible in Clinical Practice
Findings from the WIDE study
Treatment Guidance in Solid Tumours Based Upon ESCAT Is Feasible in Clinical Practice
Gustave Roussy Molecular Tumour Board stratify the genomic alterations detected in tissue/liquid biopsy based on ESCAT
Quality of Life Improvement Greater with Front-Line Pembrolizumab Compared with Chemotherapy in mCRC
Time to deterioration on several key functioning scales in KEYNOTE-177 was longer with pembrolizumab
No Improvement in Survival with Avelumab Added to CRT in Locally Advanced SCCHN
Interim results of the phase III JAVELIN head & neck 100 study in locally advanced squamous cell carcinoma of the head and neck
More Study Warranted to Determine Benefit of Neoadjuvant Durvalumab in Early-Stage NSCLC
Findings from the IFCT-1601 IONESCO study